-
Benlysta®
Benlysta® (belimumab) is an advanced biologic infusion therapy used to treat autoimmune conditions by helping regulate an overactive immune system. At Singlepoint Healthcare, Benlysta® IV therapy is delivered in a comfortable, closely monitored setting, with a focus on safety, personalized care, and long-term symptom management.
How Benlysta® Works
Benlysta® is a prescription biologic medication that targets specific proteins involved in autoimmune activity. It is most commonly used to treat systemic lupus erythematosus (SLE) and lupus nephritis, conditions in which the immune system mistakenly attacks healthy tissues.
Administered via intravenous infusion, Benlysta® helps calm immune activity, reduce disease flares, and support better disease control over time. It is often prescribed as part of a long-term treatment plan and used alongside other therapies to help patients maintain stability and prevent progression of autoimmune symptoms.
Key Details
Important Information
| Category | Details |
|---|---|
| Conditions It Treats | Systemic lupus erythematosus (SLE), Lupus nephritis |
| Manufacturer | GSK (GlaxoSmithKline) |
| Administered by | Infusion |
| Frequency | Based on diagnosis |
| Length of Infusion | ~1 hour |
| FDA Approval(s) | Systemic lupus erythematosus (SLE): March 9, 2011 Lupus nephritis: December 17, 2020 |